Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis

  • Aeterna Zentaris Inc AEZS has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD).
  • The investigational new drug application multicenter, open-label trial will investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as a growth hormone stimulation test (GHST) in pediatric patients with suspected GHD.
  • The macimorelin test will be compared to clonidine and an arginine test. Both are known standard stimulation tests.
  • The study is expected to enroll approximately 100 participants.
  • Patient enrollment on track to start this quarter, with trial completion expected in Q3 2022.
  • Under new terms and conditions of the license agreement revised in November 2020, Aeterna will coordinate the activities related to the development of macimorelin in CGHD through a joint steering committee with Novo Nordisk A/S NVO.
  • Price Action: AEZS shares are trading 2.91% higher at $0.91 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareContractsFDAGeneralBriefsGrowth Hormone
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!